Parkinson’s disease (PD) is a debilitating brain disorder that occurs when dopaminergic neurons in the brain become impaired, leading to impaired coordination, tremors, muscle rigidity, and eventually cognitive deterioration. While PD is traditionally considered a non-genetic disorder, recent studies have show that leucine-rich repeat kinase 2 (LRRK2) protein is directly linked to the disease. The Proteus team has developed a detailed molecular understanding of one of the most prevalent disease-related LRRK2 mutations, G2019S. With this insight and our parallel drug discovery/drug design platform, Proteus is pursuing a novel class of LRKK2 inhibitors that demonstrate specificity and selectivity for patients with familial PD, as well as pre-Parkinson’s patients that carry LRRK2 mutations. For more information on our PD initiative and other targets, see our Pipeline page.